跳至主要内容
临床试验/NCT05442151
NCT05442151招募中不适用

Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts

Tadashi Watabe1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2022年5月9日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
1
主要终点
Time course of uptake on FAPI-PET

研究概览

简要总结

PET / CT examination using [18F] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.

详细描述

Cancer stroma accounts for more than 90% of all tumors, and cancer-related fibroblasts (CAFs) play an important role in the growth and progression of cancer. FAP expressed in CAF has been found to be expressed in many cancers, and [68Ga] FAPI-04 and [18F] FAPI-74, which are PET diagnostic agents for FAP ligand FAPI, have been used all over the world. The purpose of this study is to perform PET / CT using [18F] FAPI-74 injection for patients diagnosed with malignant tumors, mainly pancreatic cancer and gastric cancer to evaluate the pathology in detail by comparing with the FDG-PET/CT.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients who meet any of the following conditions.
  • Patients who have been diagnosed with malignant tumors or suspected of having malignant tumors and have CT or FDG-PET examination.
  • Patients who have been diagnosed with malignant tumor and are scheduled to receive or have undergone anticancer treatment such as chemotherapy or radiation therapy.
  • Patients suspected of recurrence by clinical findings or diagnostic imaging such as CT or FDG-PET after treatment of malignant tumor

排除标准

  • Pregnant women or patients who may be pregnant
  • Pediatric patients requiring sedation
  • Those who are judged to be inappropriate as subjects.

研究组 & 干预措施

FAPI-PET/CT group

Other

干预措施: PET/CT ([F-18]FAPI-74) (Drug)

结局指标

主要结局

Time course of uptake on FAPI-PET

时间窗: Approximately 6 months after initial FAPI-PET

Time course of uptake on FAPI-PET before and after treatment compared with conventional imaging

Comparison of the uptake on FAPI-PET with conventional imaging

时间窗: Within 2 hours after administration of [F-18]FAPI-74 injection

Comparison of SUV (standardized uptake value) of primary site and metastatic lesions between FAPI-PET and FDG-PET

Comparison with pathological specimens

时间窗: Within one month after FAPI-PET

Comparison of expression level (staining score) in FAP immunostaining and SUV in FAPI-PET (FAP staining is graded by scoring evaluation: high expression (3 points), moderate expression (2 points), mild expression (1 point), and no significant expression (0 point).)

次要结局

未报告次要终点

研究者

发起方
Tadashi Watabe
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Tadashi Watabe

Assistant Professor

Osaka University

研究点 (1)

Loading locations...

相似试验